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Suppressed antibody and interleukin-6 responses to acute pyelonephri.
us in pregnancy. This study examined the effect of pregnancy on the
host response to acute pyelonephritis. Urine and serum samples were
obtained at the time of diagnosis and after two weeks, from non-
pregnant and pregnant women with acute pyelonephritis. The samples
were analyzed for interleukin-6 (IL-6) and specific antibody activity to
antigens extracted from the Escherichia coli strain infecting each
patient. The host response to infection was further quantitated as fever,
C-reactive protein, and renal concentrating capacity. Acute pyelone-
phritis in non-pregnant and pregnant women was accompanied by a
significant serum and urine antibody response. The serum antibody
response was significantly lower in the pregnant group. The IL-6 levels
in serum and urine at diagnosis were significantly higher in the non-
pregnant compared to the pregnant women. These results demonstrate
that the immunosuppression of pregnancy includes the mucosal IL-6
and specific antibody responses to acute pyelonephritis caused by
E.coli.
Urinary tract infections [UTI] elicit a host response which
includes the production of specific antibodies and the secretion
of cytokines. While uninfected urine contains immunoglobulin
and immunoglobulin fragments [1—3], it has little specific anti-
body activity against the bacterial pathogens which commonly
cause UTI [4, 5]. Bacterial infections, on the other hand,
stimulate both local and systemic immune responses [5—8].The
urinary antibody response to Escherichia coli is dominated by
secretory IgA (sigA) [2—8], but the levels of monomeric IgA and
IgG in urine may also rise during acute infection [9]. E.coli also
activate mucosal and systemic cytokine responses. Interleu-
kin-6 (IL-6) is secreted into the urine of patients with acute
pyelonephritis and asymptomatic bacteriuria (ABU) [10, 11].
The serum IL-6 levels are elevated in patients with acute
pyelonephritis, but not in those with ABU [10, 11].
Pregnant women run an increased risk of developing acute
pyelonephritis, suggesting an impaired resistance to infection
[12—16]. Pregnancy is accompanied by suppression of the host's
immune response, such as reduced cytotoxic and increased
suppressor T-cell activity [17—22]. The in vitro response of
peripheral blood lymphocytes to concanavalin-A is impaired,
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but the responses to pokeweed mitogen and phythemagglutinin
are intact [17—19]. The studies on immunoglobulin levels and
antibody activity are partly conflicting. Bisset et a! found
reduced circulating IgG but intact 1gM levels in pregnant
women [20]. Kumar, Madden and Nankervis saw no change in
antibodies to cytomegalo- and herpes simplex virus but a
decreased cellular immune response to the same agents [211.
A suppressed immune response might contribute to the
susceptibility of pregnant women to symptomatic UTI. The
influence of pregnancy on the mucosal immune response has
not been extensively studied. The aim of the present study was
to examine the influence of pregnancy on the IL-6 and specific
antibody responses to acute pyelonephritis caused by E. coli.
Methods
Patients
The non-pregnant and pregnant women participated in a
prospective study of acute pyelonephritis [23, 241. Enrollment
took place at the Infectious Diseases Clinic, GOteborg, Sweden
or at either of the two maternity hospitals serving the study
population. Diagnosis, treatment and follow-up were performed
according to a standardized protocol [24].
Diagnostic criteria and treatment
All patients had significant bacteriuria defined as  l0
colony forming units of one bacterial strain per ml of freshly
voided midstream urine. The clinical diagnosis of acute pyelo-
nephritis was made in patients who had fever  38.0°C with
costo-vertebral angle tenderness and/or loin pain. Dysuria,
frequency of urination, nausea, vomiting and chills were other
frequent symptoms. The patients diagnosed as having acute
pyelonephritis were tested for C-reactive protein (CRP) in the
serum and had their renal concentrating capacity determined
[23]. The serum CRP concentration in mg/liter was measured by
radial immunodiffusion at the time of diagnosis. Levels greater
than 25 mg/liter were considered elevated. The maximal renal
concentrating capacity was determined as the osmolarity
(mOsm/kg) in two consecutive urine samples obtained after 16
hours of fluid deprivation. The higher value of the two was
chosen. Each patient received a two week course of antimicro-
bial therapy. The choice of drug was based on the antibiotic
sensitivity pattern of the infecting strain.
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Sample collection and culture
Serum and urine specimens were obtained at the start of
treatment and two weeks later. All samples were stored at
—20°C prior to analysis. Urine and blood samples for culture
were obtained prior to treatment. Isolated bacteria were iden-
tified to the species level by standard bacteriological techniques
and stored as deep agar stabs. Extensive information on the
O:K:H serotypes and virulence factors of the isolated E.coli
strains have been presented elsewhere [24, 25].
Determination of spec jfic antibody activity
The antibody response was analyzed in patients with infec-
tions caused by E.coli, who had serum and urine samples taken
at diagnosis and two weeks later. This subsample consisted of
48 non-pregnant women (median age 52 years, range 19 to 80)
and 19 pregnant women (median age 26 years, range 20 to 36).
One pregnant and 14 non-pregnant women had positive blood
cultures.
Antigen extracts were prepared from the E.coli strain infect-
ing each patient, as previously described [26]. Briefly, each
strain was cultured overnight on solid medium and harvested
into phosphate-buffered saline (PBS, pH 7.2, 0.1 mM). The
number of bacterial cells in the suspension was determined as
the optical density at 595 nm. The bacterial suspension was
boiled for two hours in a water bath. The bacterial fragments
were sedimented by centnfugation at 2000 x g for 20 minutes,
and the supernatants used as antigens. The concentration of the
antigen extract was adjusted by dilution in PBS to correspond
to a bacterial concentration of 2 x iO bacteria/mI. This
procedure was previously shown to yield comparable amounts
of heat-stable antigens from different E.coli strains [26]. A pool
of E.coli antigen extracts was used as a control. These extracts
were prepared from E.coli strains of the serogroups which
commonly cause UT! (01, 02, 04, 06, 07, 08, 016, 018, 025
and 075) [27].
Microtitre plates (Nunc, Copenhagen, Denmark) were coated
with 0.1 ml of the control pooi of antigens or the heat-stable
antigen extracts from the individual E. coli strains. The coating
procedure was previously shown to result in an antigen excess
sufficient for the detection of antibodies to different antigenic
specificities within the extracts [26]. The plates were incubated
for four hours at 37°C and overnight at + 4°C. Unbound antigen
was removed by repeated washing with PBS containing 0.05%
Tween 20 (PBS-Tween).
Urine and serum samples were diluted in PBS-Tween. Urine
samples were analyzed at a 1:2 dilution. Serum samples were
diluted 1:100, 1:1000 and 1:10000. The samples were added in
duplicate (0.1 mI/well) and incubated for four hours at 37°C.
Unbound antibody was removed by repeated washing with
PBS-Tween. The bound antibody was detected using alkaline
phosphatase conjugated goat anti-human IgG, IgA and 1gM
(Orion, Helsinki, Finland). The antibody conjugates were di-
luted according to the manufacturer's instructions and used at
0.1 ml per well. After incubation at room temperature for 16
hours, unbound conjugate was removed by washing with PBS-
Tween. The substrate (p-nitrophenyl phosphate) was added to
each well (100 s1 of a 1 mg/mi solution) and incubated at 37°C.
The antibody activity was given as the optical density at 405 nm
after 100 minutes of incubation with the substrate.
Each sample dilution was run in duplicate in: (i) uncoated
microtitre wells; (ii) wells coated with the antigen extract from
the infecting E.coli strain; and, (iii) wells containing the control
antigen pool. A serum sample serving as a positive control was
run in wells coated with the control antigen pool. This serum
sample had high anti-E.coli antibody activity and was obtained
from a patient who had a history of multiple episodes of acute
pyelonephritis. The antibody activity in the serum samples from
each patient was expressed as a percentage of the antibody
activity of the serum control. The antibody activity of the urine
samples was given as the optical density x 10.
IL-6 determination in urine and serum
Samples (29 unnes and 28 serum samples) for IL-6 measure-
ments were available from 29 non-pregnant women with a
median age of 33 years (range 19 to 67). Samples (18 urines and
12 serum samples) were available from 18 pregnant women with
a median age of 24 years (range 20 to 36). One pregnant and
seven non-pregnant women had positive blood cultures.
The cell line B 13.29 which is dependent on IL-6 for its growth
has been described [281. For IL-6 determinations the more
sensitive subclone B9 was used [29]. The B9 cells were har-
vested from the tissue culture flasks, and 5000 cells per well
were seeded into microtiter plates (Nunc, Roskilde, Denmark)
containing dilutions of sample or recombinant human IL-6 (as a
standard) and Iscoves Modified Dulbeccos Medium supple-
mented with 50 m 2-mercapto-ethanol, 5% fetal calf serum
(Sera-Lab, Sussex, UK) and gentamicin (0.1 mg/mI), in a total
volume of 0.2 ml. [5H]-thymidine was added between 68 and 72
hours of culture, and the incorporated radioactivity was mea-
sured and compared to a standard curve. The standard curve
was prepared using stock recombinant human IL-6 (8000 U/mI;
one unit = the concentration of IL-6 required for half maximal
thymidine incorporation). The activities of each sample are
given as U/mi when compared to the standard curve.
Statistical methods
Differences between groups were evaluated using the Mann-
Whitney U test. Pairwise comparisons were performed by
Wilcoxon's signed rank test. Two-tailed tests were used and P
<0.05 was considered as statistically significant. Correlations
between parameters were tested using linear regression.
Results
Serum antibody response to acute pyelonephritis in non-
pregnant and pregnant women
Paired serum samples were obtained from 48 non-pregnant
women at the time of diagnosis and after two weeks. The IgG,
IgA, and 1gM antibody activities are shown for each patient in
Figure 1. The median and range values of IgG, IgA, and 1gM at
diagnosis and after two weeks are shown in Table 1. We
compared the values at the time of diagnosis with those
obtained at the two week follow-up in the individual patients
using the Wilcoxon signed rank test. There was a significant
increase in the serum IgG, IgA and 1gM antibody activity in the
non-pregnant group (Table 1).
Paired serum samples were obtained from 19 pregnant
women at the time of diagnosis and after two weeks. The IgG,
IgA and 1gM antibody activities for the individual patients are
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shown Figure 1. The median and range IgG, IgA and 1gM
antibody activities at diagnosis and after two weeks are shown
in Table 1. The antibody activity at the time of diagnosis and
after two weeks were compared using the Wilcoxon signed rank
test. There was a significant increase in IgG, IgA and 1gM
antibody titers between diagnosis and the two week follow-up
(Table 1).
The magnitude of the antibody responses was compared
between the pregnant and non-pregnant groups at the time of
diagnosis and two weeks later (Table 2). The net increase in
antibody activity was significantly higher in the non-pregnant
than in the pregnant group, as determined by the Mann-
Whitney U test. There was a significant difference in serum
antibody activity between the non-pregnant and pregnant
groups at time of diagnosis (IgG, P =0.011; and IgA, P 0.003)
and at the two week follow-up (IgG, P =0.003; IgA, P = 0.003;
and 1gM, P = 0.003).
The ages ranged from 19 to 80 years in the non-pregnant
group and from 20 to 36 years in the pregnant group. To exclude
the confounding influence of age variation in the analysis of the
antibody responses, we compared a subset of 13 non-pregnant
women (19 to 37 years) to the 19 pregnant women (20 to 36
years) using the Mann-Whitney U test. The differences in
antibody responses between the age-matched non-pregnant and
pregnant groups were maintained (Table 2).
Antibody
Antibody activity (median and range)
At diagnosis After 2 weeks P
Serum"
Non-pregnant
IgG 84.5 (29—166) 107 (63—369) 0.001
IgA 127 (36—809) 298.5 (78—6897) 0.001
1gM 57.5 (9—558) 159.5 (19—3786) 0.001
Pregnant
IgO 64 (22—116) 75 (29—120) 0.005
IgA 67 (5—153) 114 (21—452) 0.019
1gM 37 (19—77) 65 (24—335) 0.003
Urinec
Non-pregnant
IgG 126 (0—1299) 78.5 (0—1216) 0.001
IgA 54.5 (9—838) 50 (0—1966) 0.001
Pregnant
IgG 31(0—210) 56 (0—250) 0.043
IgA 35 (0—149) 54 (0—304) NS
a pvalue for the difference in paired samples in individual patients at
the two dates (Wilcoxon signed rank test; significance <0.05). NS is not
significant.
b Serum antibody activity given in percent of the control.
C Urinary antibody activity given as the absorbance at 405 nm after
100 minutes incubation with substrate.
Table 2. Change in antibody activity in serum and urine of non-
pregnant and pregnant women with acute pyelonephritis
Antibodyb
Change in antibody activitya
(median, range)
Non-pregnant Pregnant P
All patients (N 48) (N = 19)
Serum
IgG 20 (—46—277) 10 (— 16—45) 0.003
IgA 133 (—442—6833) 21 (—31—432) 0.003
1gM 87 (—424—3630) 17 (—22—298) 0.003
Urine
IgG —22 (—919—1050) 27.5 (—78—127) NS
IgA —9 (—681—1925) 15 (—39—234) NS
Age-matched subgroup (N = 13) (N 19)
Serum
IgG 13 (—7—277) 10 (—16—45) 0.003
IgA 90 (—442—2390) 21 (—31—432) 0.003
1gM 87 (—424—3630) 17 (—22—298) 0.003
Urine
IgG —22 (—408—97) 27.5 (—78—127) NS
IgA —9 (—304—177) 15 (—39—234) NS
O The antibody activity in the sample obtained at the time of diagnosis
was subtracted from that of the two week follow-up. The change is
given as the median difference in antibody activity in each patient
group.
b See footnote Table 1.
CP value for the difference between the non-pregnant and the
pregnant group (Mann-Whitney U test; significance <0.05). NS is not
significant.
Urinary antibody response to acute pyeionephritis in non-
pregnant and pregnant women
Paired urine samples were obtained from 48 non-pregnant
women at the time of diagnosis and after a two week follow-up.
The IgG and IgA antibody activities in urine are shown for each
patient in Figure 2. The median and range values of lgG and IgA
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Fig. 1. Serum antibody activity (lgG, igA, 1gM) at the time of diagno-
sis of acute pyelonephritis and at the 2 week follow-up. Samples from
the non-pregnant (A) and pregnant (B) women are shown separately.
Samples obtained from each patient are connected with a solid line.
0 2 0 2
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in urine at diagnosis and after two weeks are shown in Table 1.
We compared the values at the time of diagnosis with those
obtained at the two week follow-up in the individual patients
using the Wilcoxon signed rank test. There was a significant
decrease in the uiinary IgG and IgA antibody activity in the
non-pregnant group (Table 1).
Paired urine samples were obtained from 19 pregnant women
at the time of diagnosis and after a two week follow-up. The IgG
and IgA antibody activities in urine for the individual patients
are shown Figure 2. The median and range IgG and IgA urinary
antibody activities at diagnosis and after two weeks are shown
in Table 1. There was a small increase in IgG and IgA antibody
activity between diagnosis and the two week sample in the
pregnant group.
The magnitude of the urinary antibody responses was com-
pared between the non-pregnant and pregnant groups (Table 2).
A significant difference was not found. However, there was a
significant difference in urine antibody activity between the
non-pregnant and pregnant groups at the time of diagnosis (IgU,
P = 0.03; and IgA, P = 0.019) but not after two weeks (IgU, P
= 0.497; and IgA, P = 0.156).
To exclude the confounding influence of age, we compared
the urinary antibody responses in a subset of 13 non-pregnant
women (19 to 37 years) to the 19 pregnant women (20 to 36
years). A difference in urinary antibody levels between the
non-pregnant and pregnant groups was not observed either at
diagnosis or at the two week follow-up (Table 2). Nor was there
a significant difference in the change of antibody activity
between the two sampling occasions.
Serum and urine IL-6 response to acute pyelonephritis in
non-pregnant and pregnant women
The serum and urinary IL-6 response was analyzed in sam-
ples obtained at the time of diagnosis from 29 non-pregnant and
18 pregnant women with acute pyelonephritis. The IL-6 activity
in serum and urine is shown in Figure 3. The responses in the
non-pregnant and the pregnant groups were compared using the
Mann-Whitney U test. There was a significant difference in the
serum IL-6 response between the non-pregnant and the preg-
nant groups. The mean serum IL-6 levels were 50 U/mI for the
non-pregnant and 5 U/mI for the pregnant group (P < 0.05).
Serum IL-6 levels > 20 U/mI occurred in 14 of 28 non-pregnant
compared to 1 of 12 pregnant women (P < 0.001).
There was a significant difference in the urine IL-6 response
between the two groups. The non-pregnant women with acute
pyelonephritis had a mean urinary IL-6 activity of 81 U/mi
compared to 18 U/mI in the pregnant group (P <0.02). Urinary
IL-6 levels > 20 U/mI occurred in 25 of 29 non-pregnant
compared to 3 of 18 of the pregnant women with acute pyelo-
nephritis (P <0.02).
Correlation of IL-6 with the acute phase response
The body temperature at the time of diagnosis was signifi-
cantly higher in the non-pregnant group (median 39.5°C; range
38.0 to 40°C) than in the pregnant group (median 38.8°C; range
38.1 to 41°C; P < 0.019). Since IL-6 acts as an endogenous
pyrogen, we analyzed the relationship between the serum IL-6
levels and the febrile response. There was no correlation
between the temperature and serum IL-6 levels in the pyelone-
phntis group as a whole, or in the non-pregnant (r = 0.2, P <
0.35) or pregnant patients (r = 0.3, P < 0.44) with acute
pyelonephritis.
The mean (± SD) CRP levels were significantly higher in the
non-pregnant women with acute pyelonephritis (179 125 mg/
liter) compared to the pregnant group (101 78 mg/liter; P <
0.026). 1L-6 is an activator of the CRP synthesis in the liver. We
therefore analyzed the relationship between IL-6 and CRP
levels in the serum by linear regression. There was no correla-
tion of the individual CRP and serum IL-6 levels within either
the non-pregnant or pregnant groups (r =0, P < 0.9). There was
a highly significant correlation between the fever and CRP
levels in the individual patients with acute pyelonephritis (r =
0.5, P < 0.0001).
lnterleukin-6 and antibody responses
IL-6 stimulates B lymphocyte differentiation and antibody
production. We used linear regression to analyze the possible
association of IL-6 and antibody responses in individual pa-
tients. An association between the levels of IL-6 activity in
serum and the change in serum IgG, 1gM or IgA antibodies was
not observed for the non-pregnant women with acute pyelone-
phritis (r 0.258; r 0.059; and r = 0.019, respectively).
Similarly, there was no correlation of serum IL-6 levels with
serum IgG, 1gM or IgA antibodies in the pregnant patients (r
0.232; r 0.027; and r = 0.188, respectively). Regression
analysis also showed there was no association between the
urinary IgG and IgA antibodies and urinary IL-6 levels in both
patient groups (IgG, r 0.019 and IgA, r 0.033 for the
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Fig. 2. Urine antibody activity (IgG, igA) at the time of diagnosis of
acute pyelonephritis and at the 2 week follow-up. Samples from the
non-pregnant (A) and pregnant (B) women are shown separately.
Samples obtained from each patient are connected with a solid line.
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non-pregnant group; IgG, r = 0.144 and IgA, r = 0.067 for the
pregnant group).
Discussion
This study demonstrated that pregnant women had reduced
IL-6 and serum antibody responses to acute pyelonephritis
compared to non-pregnant women. The serum IgG, IgA, and
1gM antibody activity to E.coli antigens increased in the non-
pregnant women during the two weeks following the diagnosis
of acute pyelonephritis. In contrast, the increase in serum
anti-E.coli antibody activity of the pregnant women was less
pronounced. The serum and urinary IL-6 levels were elevated
in the majority of the non-pregnant women with acute pyelone-
phritis, but low in the pregnant women at diagnosis. These
results suggest that pregnancy is accompanied by an immuno-
suppression of the active cytokine and specific antibody re-
sponses to gram-negative UT!.
The main purpose of the study was to evaluate the immune
response to acute pyelonephritis of individual patients, and the
effect of pregnancy on this response. We obtained samples from
each patient at the onset of infection and two weeks later. The
response to infection was deduced from the difference in
antibody activity between these samples. The antibody activity
in serum and urine was determined using antigens prepared
from the E.coli strain infecting each patient. The antigen
extracts contained heat-stable lipopolysaccharides and proteins
(including fimbrial proteins) from the infecting strain [261.
Broadly reactive antigen preparations were used to permit the
detection of multiple antibody specificities. This study was not
designed to analyze antibody responses to single antigen
epitopes of the bacterial strains.
The antibody response to acute pyelonephritis has been the
subject of numerous studies [5—9, 27]. The serum antibody
response which occurred among the women with acute pyelo-
nephritis in the present study was consistent with the findings in
these previous studies. Vosti, Monto and Rantz analyzed anti-O
antibodies in serum of women with acute pyelonephritis and
acute cystitis [30]. A significant rise in serum antibodies oc-
curred in 14 of 17 patients with acute pyelonephritis with the
antibody response reaching maximal levels in the third to fourth
week [30]. Andersen [27] and Jodal [31] followed the serum
antibody response to acute pyelonephntis in children. A serum
antibody response occurred in a majority of the children and
was even used as a diagnostic tool in this patient group.
In contrast, the active immune response in pregnant women
to UT! has not previously been examined. Previous studies of
antibody responses in pregnancy have focused mainly on the
pre-existing antibody levels rather than the active response to
infection. The results of this study showed that pregnant
women had a lower systemic antibody response to acute
pyelonephritis than the non-pregnant group. This might reflect a
reduced immune response or lower immunogenicity of the
E.coli strains that infect pregnant women. The E.coli clones
infecting pregnant women differ in terms of their O:K:H antigen
combinations from the clones infecting non-pregnant women.
There is, however, extensive overlap in individual antigens
such as lipopolysaccharide [LPS] and the P-fimbriae. These
antigens are known to be immunogenic and have been proposed
to be immunodominant. It is unlikely that the whole pregnant
group would be selectively infected by clones of low immuno-
genicity especially since their strains carry antigens known to
be immunogenic in other individuals. We therefore consider it
likely that the reduced host response in the pregnant group was
caused by the immunosuppression of pregnancy.
The urinary antibody response to acute pyelonephritis has
mainly been studied in children [5, 7, 8]. An increase in urinary
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pregnant and pregnant women at the time of
diagnosis of acute pyelonephritis.
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antibody activity occurred around 7 to 10 days after infection,
and was of short duration [81. The collection of urine samples in
the present study was timed according to the information from
the pediatric studies. However, the kinetics of the antibody
response among the adult women differed from the pattern seen
in children. A large fraction of the patients had elevated urinary
antibodies at the time of diagnosis. The urinary antibody
activity in those patients decreased rather than increased with
time. This antibody response was not caused by earlier UT!
episodes. Although several of the study patients had experi-
enced prior UT! episodes, these were too far in the past to
influence the urinary antibody levels at the time of enrollment in
the present study.
Previous studies in adults have shown that IL-6 is secreted
into the urine within a few hours of deliberate bacterial chal-
lenge, and that IL-6 is present in the urine at the time of
diagnosis in patients with bacteriuria [10, 11]. In this study the
pregnant women were found to have a reduced IL-6 response
during UT!. Pregnancy is accompanied by a decrease in urinary
osmolarity. It may be discussed if the apparent decrease in
urinary IL-6 levels in the pregnant women was caused by the
dilution factor rather than by a decreased production of IL-6.
Two observations argue against this hypothesis. First, there
was a concomitant decrease in serum IL-6 levels. Second, there
was no decrease in the urinary antibody levels and no associa-
tion of urinary antibodies with IL-6. This suggested that preg-
nant women have a reduced serum and urinary IL-6 responses
to UT!.
IL-6 is an endogenous pyrogen, an activator of the acute-
phase response and a stimulator of B lymphocyte differentia-
tion, especially for the IgA committed mucosal B-cells [32—35].
Pregnant women have reduced levels of host response param-
eters like fever and CRP. The low serum levels of IL-6 might
explain the reduced host responses in the pregnant group. We
attempted to correlate IL-6 activity with the temperature, CRP
and the IgA response of the individual patients. A significant
correlation between these responses was not observed. This
dilemma has previously been observed in adult patients with
acute pyelonephritis where !L-6 levels did not correlate with
the inflammatory response [11]. The role of IL-6 in the in vivo
response therefore remains to be defined. The kinetics of the
IL-6 response and the acute phase reactants may differ by some
time factor which does not allow a correlation to be made.
The immunosuppression which occurs during pregnancy
does not lead to a generalized susceptibility to infection.
However, the rate of acquisition of bacteriuria seems to be
increased during pregnancy and bacteria of reduced virulence
have been shown to cause acute pyelonephritis in pregnant
women [24, 36]. The tendency to develop acute pyelonephritis
has been attributed to the hydrodynamic changes of the urinary
tract which facilitate retrograde transport of bacteria to the
kidneys [14]. The results of the present study demonstrated that
the active immune response to UT! is impaired in pregnant
women. This raises the question whether the reduced IL-6 and
antibody responses also influence the susceptibility to acute
pyelonephritis in pregnancy.
The contribution of specific immunity and mucosal antibodies
to the resistance against UT! is not well understood. The main
evidence favoring a role of humoral immunity has been ob-
tained from studies in animal models. Hyperimmunization
protects against subsequent bacterial challenge, however, it is
not clear to what extent this protection is explained by antibod-
ies [37—39]. Several observations contradict a role of specific
immunity for the natural resistance against UT! in patients or
animals who have not been hyperimmunized. The frequency of
UT! is not increased in patients with antibody deficiencies like
hypogammaglobulinemia. Furthermore, immunodeficient mice
have intact resistance to experimental UT! [40, 41]. It is
therefore difficult to argue that the reduced antibody response
of the pregnant women is the cause of their susceptibility to
symptomatic UTI.
The resistance to experimental UTI is influenced by the
inflammatory response to infection [37—42]. E.coli fail to acti-
vate an inflammatory response in mice of the Lpsd genotype
[40, 41]. These mice are highly susceptible to E.coli UT!.
Furthermore, animals treated with anti-inflammatory agents
have impaired ability to clear experimental UT! [42]. The low
IL-6 response may indicate that pregnant women have a gen-
erally reduced level of mucosal inflammation. This may include
factors that are crucial for the elimination of infection.
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